AbbVie Inc. (ABBV), Thursday lowered its adjusted earnings per share outlook for the third quarter and the fiscal year 2024, citing acquisition-related IPR&D and milestones expenses of $82 million.
For the third quarter, the drug maker now expects adjusted EPS of $2.88 to $2.92 compared to previously estimated $2.92 to $2.96.
Analysts, on average, polled by Thomson Reuters estimate earnings to be $2.95 per share for the same period.
Additionally, AbbVie forecasts adjusted EPS of $10.67 to $10.87 compared to previously expected $10.71 to $10.91 for the full year 2024.
Analysts, on average, polled by Thomson Reuters estimate earnings to be $10.88 per share for the same period.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.